Kimio Terao

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

Norihiro Nishimoto, Kimio Terao, Toru Mima et al. · Blood · 2008 · 810 citations · Full text

Life Sciences, Immunology, Pharmacology +16

Characterization of Patients With Advanced Pancreatic Cancer and High Serum Interleukin-6 Levels

Tomofumi Miura, Shuichi Mitsunaga, Masafumi Ikeda et al. · Pancreas · 2015 · 91 citations

Medicine, Immunology, Oncology +9

Immune response to influenza vaccine and pneumococcal polysaccharide vaccine under IL-6 signal inhibition therapy with tocilizumab

Tomomi Tsuru, Kimio Terao, Miho Murakami et al. · Modern Rheumatology · 2013 · 66 citations

Pharmacy, Immunology, Pharmacotherapy +17

Pharmacokinetics and Pharmacodynamics of Tofogliflozin (a Selective SGLT2 Inhibitor) in Healthy Male Subjects

Nahoko Kasahara-Ito, Hiroyuki Fukase, Yoichiro Ogama et al. · Drug Research · 2017 · 40 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacology +14

Mechanism‐based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study)

Shuji Ohta, Tomomi Tsuru, Kimio Terao et al. · The Journal of Clinical Pharmacology · 2013 · 30 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17